Robert L Coleman, MD
A randomized phase 3, double-blind study of chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer (EOC) (KEYLYNK-001/ENGOT-ov43). NCT03740165
Coleman RL et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381(25):2403-15. Abstract
Ding L et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep 2018;25(11):2972-80. Abstract
Higuchi T et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res 2015;3(11):1257-68. Abstract
Kaplan AR et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med 2019;11(492):eaav4508. Abstract
Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9. Abstract
Liu JF et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol 2014;15(11):1207-14. Abstract
Mirza MR et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): A randomised, phase 2, superiority trial. Lancet Oncol 2019;20(10):1409-19. Abstract
Ray-Coquard I et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28. Abstract
Stephanie Lheureux, MD, PhD
Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61. Abstract
Lheureux S et al. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69(4):280-304. Abstract
Lheureux S et al. Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer — A Princess Margaret Consortium – GCIG Phase II Trial. ASCO 2019;Abstract 5521.
Lin KK et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. 2019;9(2):210-9. Abstract
Madariaga A et al. Manage wisely: Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;[Online ahead of print]. Abstract
Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274-84. Abstract
Joyce F Liu, MD, MPH
Coleman RL et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381(25):2403-15. Abstract
González-Martin A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402. Abstract
Konstantinopoulos PA et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020;38(11):1222-45. Abstract
Konstantinopoulos PA et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;5(11):1137-54. Abstract
Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract
Norquist BM et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2(4):482-90. Abstract
Pennington KP et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20(3):764-75. Abstract
Ray-Coquard I et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28. Abstract
Shah GM et al. PARP inhibitors in cancer therapy: Magic bullets but moving targets. Front Oncol 2013;3:279. Abstract
Swisher EM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18(1):75-87. Abstract
Kathleen Moore, MD
A phase 3 placebo-controlled study of carboplatin/paclitaxel with or without concurrent and continuation maintenance veliparib (PARP inhibitor) in subjects with previously untreated stages III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. NCT02470585
A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. NCT01844986
A phase 3, randomized, double-blind, placebo-controlled, multicenter study of niraparib maintenance treatment in patients with advanced ovarian cancer following response on front-line platinum-based chemotherapy. NCT02655016
Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. Abstract
du Bois A et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour Les Etudes Des Cancers De l'Ovaire (GINECO). Cancer 2009;115(6):1234-44. Abstract
Giornelli GH. Management of relapsed ovarian cancer: A review. Springerplus 2016;5(1):1197. Abstract
González-Martin A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402. Abstract
Ledermann JA et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):24-32. No abstract available
Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract
Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96. Abstract
Pignata S et al. Treatment of recurrent ovarian cancer. Ann Oncol 2017;28(Suppl 8):51-6. Abstract
Randomized, double-blind, phase III trial olaparib vs placebo patients with advanced FIGO stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated standard first-line treatment. NCT02477644
Wilson MK et al. Fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup: Recurrent disease. Ann Oncol 2017;28(4):727-32. Abstract